Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human B7-2 / CD86 Protein, Fc tag (MALS verified), 200µg  

Recombinant human B7-2 / CD86 Protein, Fc tag (MALS verified), 200µg

Recombinant Human B7-2 / CD86 (Leu 26 - Pro 247), expressed from human 293 cells (HEK293), Fc tag (MALS verified)

Synonym
CD86, B7-2, B70, CD28LG2, LAB72, MGC34413

More details

CD6-H5257-200

Availability: within 7 days

408,00 €

Background
Cluster of Differentiation 86 (CD86), also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily,[1] and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival.[2] Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.[3]

Source
Recombinant Human B7-2, Fc Tag (CD6-H5257) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # AAH40261).
Predicted N-terminus: Leu 26

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 51.5 kDa. As a result of glycosylation, the protein migrates as 66-86 kDa under reducing (R) condition, and 120-140 kDa under non-reducing (NR) condition (SDS-PAGE).

Endotoxin
Less than 1.0 EU per μg of the rhCD86-Fc by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Prevention of CD8 T Cell Deletion during Chronic Viral Infection"
Brooks, Tishon, Oldstone et al
Viruses (2021) 13 (7)
(2) "Cryptic association of B7-2 molecules and its implication for clustering"
Lankipalli, H S, Selvam et al
Protein Sci (2021)
(3) "Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19"
Julià, Bonafonte-Pardàs, Gómez et al
Sci Rep (2021) 11 (1), 11462
Showing 1-3 of 4687 papers.
Please refer to product data sheet.